14 July 2021 - The TGA has updated its list of applications for new medicines/vaccines or new uses for existing medicines/vaccines that are currently under evaluation.

The list increased by 18 in June:

• Cytosine arabinoside with daunorubicin (nanoparticle, liposomal) - new combination product
• Agomelatine - new indication
• Ravulizumab - new indication
• Beclomethasone dipropionate with eformoterol) fumarate dihydrate and glycopyrronium bromide - new indication
• Thiotepa - new indication
• Diphtheria toxoid; haemophilus influenza type b polyribose ribitol phosphate; pertactin; pertussis filamentous haemagglutinin; pertussis fimbriae 2 + 3; pertussis toxoid; poliovirus; tetanus toxoid; hepatitis b surface antigen - new vaccine. The TGA has described this as a new medicine.
• Somapacitan - new medicine
• Varicella zoster virus vaccine (adjuvanted) - new indication
• Lenvatinib mesylate - new indication
• Pembrolizumab - new indication (renal cell carcinoma)
• Pembrolizumab - new indication (squamous cell carcinoma)
• Nitric oxide - new indication
• Human papilloma virus vaccine (9 valent) - new indication
• Influenza vaccine (quadrivalent, split virion) - new indication
• Dupilimab - new indication (asthma)
• BNT162b2 - new indication
• Oestradiol hemihydrate with progesterone - new combination product
• Glucagon - new formulation. The TGA has described this as a new medicine.

Read TGA News